fibrin modulating drug - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	fibrin modulating drug	go back to main search page
Accession:	CHEBI:48676	browse the term
Definition:	A drug that affects the function of fibrin in blood coagulation.
Synonyms:	related_synonym:	fibrin modulating agent; fibrin modulating agents; fibrin modulating drugs

show annotations for term's descendants Sort by:
Rat (165) Mouse (166) Human (167) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (167)

6-aminohexanoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Aminocaproic Acid results in decreased expression of A2M protein

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

folate hydrolase 1

multiple interactions

[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein]

NCBI chr11:49,145,092...49,208,602
Ensembl chr11:49,145,092...49,208,638

G

gastrin releasing peptide receptor

multiple interactions

[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [bombesin, Tyr(4)- binds to GRPR protein]

NCBI chr X:16,123,565...16,153,518
Ensembl chr X:16,123,565...16,153,518

G

mitogen-activated protein kinase 1

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

plasminogen

multiple interactions

Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]; Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097

G

serpin family C member 1

increases expression

Aminocaproic Acid results in increased expression of SERPINC1 protein

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

anagrelide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Fli-1 proto-oncogene, ETS transcription factor

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of FLI1 mRNA]

NCBI chr11:128,685,351...128,813,267
Ensembl chr11:128,686,535...128,813,267

G

GATA binding protein 1

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 protein]

NCBI chr X:48,786,590...48,794,311
Ensembl chr X:48,786,540...48,794,311

G

integrin subunit alpha 2b

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of ITGA2B mRNA]

NCBI chr17:44,372,181...44,389,649
Ensembl chr17:44,372,180...44,389,649

G

MPL proto-oncogene, thrombopoietin receptor

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of MPL mRNA]

NCBI chr 1:43,337,818...43,354,466
Ensembl chr 1:43,337,818...43,354,466

G

nuclear factor, erythroid 2

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of NF-E2 mRNA]

NCBI chr12:54,292,111...54,301,015
Ensembl chr12:54,292,111...54,301,015

G

platelet derived growth factor subunit B

increases expression

anagrelide results in increased expression of PDGFB mRNA

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

transforming growth factor beta 1

decreases expression

anagrelide results in decreased expression of TGFB1 mRNA

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

thrombopoietin

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of FLI1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 protein]; anagrelide inhibits the reaction [THPO protein results in increased expression of ITGA2B mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of MPL mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of NF-E2 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of ZFPM1 mRNA]

NCBI chr 3:184,371,935...184,379,688
Ensembl chr 3:184,371,935...184,381,968

G

zinc finger protein, FOG family member 1

multiple interactions

anagrelide inhibits the reaction [THPO protein results in increased expression of ZFPM1 mRNA]

NCBI chr16:88,451,769...88,537,031
Ensembl chr16:88,453,280...88,537,031

camostat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholecystokinin A receptor

increases expression

camostat results in increased expression of CCKAR mRNA

NCBI chr 4:26,481,396...26,490,484
Ensembl chr 4:26,481,396...26,490,484

G

C-C motif chemokine ligand 2

multiple interactions

camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

cellular communication network factor 2

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA]

PMID:25766432 PMID:27773435

NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372

G

cyclin D1

increases expression
multiple interactions

camostat results in increased expression of CCND1 protein
mirdametinib inhibits the reaction [camostat results in increased expression of CCND1 protein]

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cyclin D3

increases expression
multiple interactions

camostat results in increased expression of CCND3 protein
mirdametinib inhibits the reaction [camostat results in increased expression of CCND3 protein]

NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357

G

cyclin E1

multiple interactions
increases expression

mirdametinib inhibits the reaction [camostat results in increased expression of CCNE1 protein]

NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312

G

collagen type I alpha 1 chain

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of COL1A1 mRNA]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type III alpha 1 chain

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of COL3A1 mRNA]

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

cytochrome b-245 beta chain

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of CYBB mRNA]

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

early growth response 1

increases expression
multiple interactions

camostat results in increased expression of EGR1 mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of EGR1 mRNA]

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

fibroblast growth factor 21

multiple interactions

camostat results in increased expression of and results in increased secretion of FGF21 protein

NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

mirdametinib inhibits the reaction [camostat results in increased expression of FOS mRNA]

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

immediate early response 3

increases expression

camostat results in increased expression of IER3 mRNA

NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation
increases expression

camostat results in increased phosphorylation of JUN protein
camostat results in increased expression of JUN mRNA

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

camostat results in increased expression of JUNB mRNA

NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

camostat results in increased phosphorylation of MAPK1 protein
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

marker of proliferation Ki-67

increases expression
multiple interactions

camostat results in increased expression of MKI67 protein
mirdametinib inhibits the reaction [camostat results in increased expression of MKI67 protein]

NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423

G

nitric oxide synthase 3

increases expression

camostat results in increased expression of NOS3 mRNA

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NADPH oxidase 1

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of NOX1 mRNA]

NCBI chr X:100,843,324...100,874,359
Ensembl chr X:100,843,324...100,874,359

G

proliferating cell nuclear antigen

increases expression
multiple interactions

camostat results in increased expression of PCNA protein
mirdametinib inhibits the reaction [camostat results in increased expression of PCNA protein]

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

plasminogen

multiple interactions
decreases activity

camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
camostat results in decreased activity of PLG protein modified form

NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097

G

ribosomal protein S6

increases phosphorylation

camostat results in increased phosphorylation of RPS6 protein

NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236

G

serpin family E member 1

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of SERPINE1 mRNA]

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

SMAD family member 2

multiple interactions

camostat inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD2 protein]

NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146

G

signal transducer and activator of transcription 3

increases phosphorylation

camostat results in increased phosphorylation of STAT3 protein

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

transforming growth factor beta 1

multiple interactions

camostat inhibits the reaction [Adenine results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]
camostat inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]

PMID:25766432 PMID:26599507 PMID:27773435

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transmembrane serine protease 2

decreases activity

camostat results in decreased activity of TMPRSS2 protein

NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116

G

tumor necrosis factor

multiple interactions

camostat inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]

PMID:20023007 PMID:27773435

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

cilostazol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

cilostazol increases expression of abca1 protein in liver
cilostazol reverses the reaction [palmitate decreases expression of abca1 protein in hepatoma cells]

RGD

PMID:26362727 PMID:26362727

RGD:21408552, RGD:21408552

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions

[Meloxicam co-treated with Cilostazol] results in decreased expression of ABL1 protein

NCBI chr 9:130,713,043...130,887,675
Ensembl chr 9:130,713,043...130,887,675

G

apoptosis inducing factor mitochondria associated 1

increases localization

cilostazol results in increased localization of AIFM1 protein

NCBI chr X:130,129,362...130,165,841
Ensembl chr X:130,124,666...130,165,879

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

[Meloxicam co-treated with Cilostazol] results in decreased phosphorylation of AKT1 protein; Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]; iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; paxilline inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; PTEN affects the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]]
cilostazol results in increased phosphorylation of AKT1 protein

PMID:12807996 PMID:15978173 PMID:18556572 PMID:35920412

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

anti-Mullerian hormone

multiple interactions

Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]

NCBI chr19:2,249,323...2,252,073
Ensembl chr19:2,249,309...2,252,073

G

amyloid beta precursor protein

multiple interactions
affects expression

(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]; KT 5720 inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]
cilostazol affects the expression of APP protein

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

affects expression

cilostazol affects the expression of ATP2A2 mRNA; cilostazol affects the expression of ATP2A2 protein

NCBI chr12:110,280,616...110,351,093
Ensembl chr12:110,280,756...110,351,093

G

BCL2 associated X, apoptosis regulator

increases expression
affects expression
multiple interactions

Cilostazol results in increased expression of BAX mRNA; Cilostazol results in increased expression of BAX protein
cilostazol affects the expression of BAX protein
[Cilostazol co-treated with Meloxicam] results in increased expression of BAX mRNA; Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

PMID:15978173 PMID:16822680 PMID:20131233 PMID:35920412

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
affects expression
decreases expression

cilostazol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
cilostazol affects the expression of BCL2 protein
cilostazol results in decreased expression of BCL2 protein

PMID:15978173 PMID:16822680 PMID:20131233

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BH3 interacting domain death agonist

multiple interactions

cilostazol inhibits the reaction [Nitroprusside results in decreased expression of BID protein modified form]; cilostazol inhibits the reaction [Nitroprusside results in increased cleavage of and results in increased localization of BID protein]

NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770

G

caspase 3

multiple interactions
increases activity

[Meloxicam co-treated with Cilostazol] results in increased activity of CASP3 protein; KT 5720 inhibits the reaction [Cilostazol results in increased activity of CASP3 protein]
Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP3 protein]

PMID:18311796 PMID:20131233 PMID:32456565 PMID:35920412

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

multiple interactions

cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP7 protein]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

caspase 8

multiple interactions

cilostazol inhibits the reaction [Nitroprusside results in increased activity of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

caspase 9

increases activity
multiple interactions

Cilostazol results in increased activity of CASP9 protein
[Meloxicam co-treated with Cilostazol] results in increased activity of CASP9 protein

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-C motif chemokine ligand 2

multiple interactions

cilostazol inhibits the reaction [TNF protein results in increased expression of CCL2]; cilostazol promotes the reaction [Probucol inhibits the reaction [TNF protein results in increased expression of CCL2]]; Probucol promotes the reaction [cilostazol inhibits the reaction [TNF protein results in increased expression of CCL2]]

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

cyclin A2

decreases expression

cilostazol results in decreased expression of CCNA2 protein

NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883

G

cyclin dependent kinase inhibitor 1A

increases expression

cilostazol results in increased expression of CDKN1A protein

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

CF transmembrane conductance regulator

multiple interactions
increases activity

cilostazol promotes the reaction [CFTR protein affects the secretion of Chlorides]
cilostazol results in increased activity of CFTR protein

NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation

cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]; iberiotoxin inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; PTEN affects the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]]
cilostazol results in increased phosphorylation of CREB1 protein

PMID:12807996 PMID:15978173

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

casein kinase 2 alpha 1

increases phosphorylation
multiple interactions

cilostazol results in increased phosphorylation of CSNK2A1 protein
(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid inhibits the reaction [cilostazol results in increased phosphorylation of CSNK2A1 protein]; CSNK2A1 protein affects the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]; KT 5720 inhibits the reaction [cilostazol results in increased phosphorylation of CSNK2A1 protein]

NCBI chr20:472,498...543,790
Ensembl chr20:472,498...543,835

G

E2F transcription factor 1

decreases expression

cilostazol results in decreased expression of E2F1 protein

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

E2F transcription factor 2

decreases expression

cilostazol results in decreased expression of E2F2 protein

NCBI chr 1:23,505,212...23,531,233
Ensembl chr 1:23,506,438...23,531,233

G

E1A binding protein p300

affects expression
multiple interactions

cilostazol affects the expression of EP300 protein
(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid inhibits the reaction [cilostazol affects the expression of EP300 protein]; KT 5720 inhibits the reaction [cilostazol affects the expression of EP300 protein]; SIRT1 protein affects the reaction [cilostazol affects the expression of EP300 protein]; sirtinol inhibits the reaction [cilostazol affects the expression of EP300 protein]

NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077

G

follicle stimulating hormone subunit beta

multiple interactions

Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]

NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261

G

glycogen synthase kinase 3 beta

affects phosphorylation
multiple interactions

cilostazol affects the phosphorylation of GSK3B protein
SIRT1 protein affects the reaction [cilostazol affects the phosphorylation of GSK3B protein]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

heme oxygenase 1

increases response to substance
increases expression
multiple interactions

HMOX1 results in increased susceptibility to cilostazol
cilostazol results in increased expression of HMOX1 mRNA; cilostazol results in increased expression of HMOX1 protein
copper protoporphyrin IX inhibits the reaction [cilostazol results in increased expression of HMOX1 protein]; HMOX1 mutant form inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; HMOX1 mutant form inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; HMOX1 mutant form inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; HMOX1 protein promotes the reaction [cilostazol results in increased activity of PPARG protein]; NFE2L2 mutant form inhibits the reaction [cilostazol results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of HMOX1 protein]
Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Cilostazol inhibits the reaction [Nitroprusside results in decreased expression of HMOX1 protein]

PMID:18311796 PMID:20131233 PMID:21256160 PMID:21660147 PMID:32456565

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

interleukin 1 beta

multiple interactions
decreases expression

cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; HMOX1 mutant form inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]
Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]
cilostazol results in decreased expression of IL1B protein

PMID:20131233 PMID:32456565

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 4

multiple interactions

cilostazol inhibits the reaction [4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone results in decreased expression of IL4 protein]

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 5

multiple interactions

cilostazol inhibits the reaction [4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone results in decreased expression of IL5 protein]

NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838

G

interleukin 6

multiple interactions
decreases expression

Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; HMOX1 mutant form inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]
Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]
cilostazol results in decreased expression of IL6 protein

PMID:20131233 PMID:32456565

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

luteinizing hormone subunit beta

multiple interactions

Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]

NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091

G

microtubule associated protein tau

multiple interactions

cilostazol affects the acetylation of and affects the phosphorylation of MAPT protein; SIRT1 protein affects the reaction [cilostazol affects the acetylation of and affects the phosphorylation of MAPT protein]

NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[Meloxicam co-treated with Cilostazol] results in decreased expression of MYC protein

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
increases response to substance

cilostazol results in increased expression of NFE2L2 protein
Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein]; Verapamil promotes the reaction [Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein]]
NFE2L2 results in increased susceptibility to cilostazol
NFE2L2 mutant form inhibits the reaction [cilostazol results in increased expression of HMOX1 protein]

PMID:20131233 PMID:30295103 PMID:32456565

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NFKB inhibitor alpha

increases expression
multiple interactions

cilostazol results in increased expression of NFKBIA protein
zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

nitric oxide synthase 2

multiple interactions

cilostazol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

nitric oxide synthase 3

multiple interactions
increases phosphorylation

cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]
cilostazol results in increased phosphorylation of NOS3 protein

PMID:18556572 PMID:19520256

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NQO1 protein]; Verapamil promotes the reaction [Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NQO1 protein]]

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

proliferating cell nuclear antigen

decreases expression

cilostazol results in decreased expression of PCNA protein

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

phospholamban

affects expression

cilostazol affects the expression of PLN mRNA; cilostazol affects the expression of PLN protein

NCBI chr 6:118,548,296...118,561,716
Ensembl chr 6:118,548,296...118,561,716

G

peroxisome proliferator activated receptor gamma

increases activity
multiple interactions

cilostazol results in increased activity of PPARG protein
2-chloro-5-nitrobenzanilide inhibits the reaction [cilostazol results in increased activity of PPARG protein]; HMOX1 protein promotes the reaction [cilostazol results in increased activity of PPARG protein]; zinc protoporphyrin inhibits the reaction [cilostazol results in increased activity of PPARG protein]

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

[Meloxicam co-treated with Cilostazol] results in increased expression of and results in increased phosphorylation of PRKAA1 protein

NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374

G

phosphatase and tensin homolog

multiple interactions
decreases phosphorylation

cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]; iberiotoxin inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]; PTEN affects the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; PTEN affects the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]]
cilostazol results in decreased phosphorylation of PTEN protein

PMID:12807996 PMID:15978173

NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930

G

prostaglandin-endoperoxide synthase 2

multiple interactions

cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

sirtuin 1

multiple interactions
increases phosphorylation
affects expression
increases expression

cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Paclitaxel results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]
cilostazol results in increased phosphorylation of SIRT1 protein
cilostazol affects the expression of SIRT1 mRNA
(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; cilostazol affects the expression of and affects the activity of SIRT1 protein; cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]; CSNK2A1 protein affects the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]; KT 5720 inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; KT 5720 inhibits the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]; SIRT1 protein affects the reaction [cilostazol affects the acetylation of and affects the phosphorylation of MAPT protein]; SIRT1 protein affects the reaction [cilostazol affects the expression of EP300 protein]; SIRT1 protein affects the reaction [cilostazol affects the phosphorylation of GSK3B protein]; sirtinol inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]
cilostazol results in increased expression of SIRT1 protein

PMID:18556572 PMID:19520256 PMID:24254769

NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390

G

solute carrier family 22 member 2

multiple interactions

cilostazol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638

G

solute carrier family 29 member 1 (Augustine blood group)

multiple interactions

Cilostazol inhibits the reaction [4-nitrobenzylthioinosine binds to SLC29A1 protein]; Cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]

NCBI chr 6:44,219,615...44,234,142
Ensembl chr 6:44,219,553...44,234,142

G

superoxide dismutase 1

multiple interactions

[Verapamil co-treated with Cilostazol] inhibits the reaction [Thioacetamide results in decreased activity of SOD1 protein]; Cilostazol inhibits the reaction [Thioacetamide results in decreased activity of SOD1 protein]

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

tumor necrosis factor

multiple interactions
decreases response to substance
decreases expression

[Cilostazol co-treated with Probucol] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Cilostazol inhibits the reaction [TNF protein results in increased expression of CCL2]; Cilostazol inhibits the reaction [TNF protein results in increased expression of VCAM1]; Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]; Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]; Cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]; Cilostazol promotes the reaction [Probucol inhibits the reaction [TNF protein results in increased expression of CCL2]]; Cilostazol promotes the reaction [Probucol inhibits the reaction [TNF protein results in increased expression of VCAM1]]; HMOX1 mutant form inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]; paxilline inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; paxilline inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; paxilline inhibits the reaction [Cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]; Probucol promotes the reaction [Cilostazol inhibits the reaction [TNF protein results in increased expression of CCL2]]; Probucol promotes the reaction [Cilostazol inhibits the reaction [TNF protein results in increased expression of VCAM1]]; PTEN affects the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; PTEN affects the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]]; PTEN affects the reaction [iberiotoxin inhibits the reaction [Cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]]; zinc protoporphyrin inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Cilostazol results in decreased susceptibility to TNF protein]
Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]
cilostazol results in decreased susceptibility to TNF protein
cilostazol inhibits the reaction [4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone results in decreased expression of TNF protein]; cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
cilostazol results in decreased expression of TNF protein

PMID:12807996 PMID:15169552 PMID:19967051 PMID:20131233 PMID:21256160 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

increases expression
multiple interactions

cilostazol results in increased expression of TP53 protein
cilostazol inhibits the reaction [Nitroprusside results in increased phosphorylation of TP53 protein]

PMID:10642304 PMID:18311796

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

vascular cell adhesion molecule 1

multiple interactions

cilostazol inhibits the reaction [TNF protein results in increased expression of VCAM1]; cilostazol promotes the reaction [Probucol inhibits the reaction [TNF protein results in increased expression of VCAM1]]; Probucol promotes the reaction [cilostazol inhibits the reaction [TNF protein results in increased expression of VCAM1]]

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

clopidogrel

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1

multiple interactions
decreases uptake
decreases expression
increases secretion
affects response to substance
decreases activity

ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]
[Aspirin results in increased expression of ABCB1 protein] which results in decreased uptake of clopidogrel
ABCB1 protein results in decreased uptake of clopidogrel
clopidogrel results in decreased expression of ABCB1 mRNA; clopidogrel results in decreased expression of ABCB1 protein
ABCB1 protein results in increased secretion of clopidogrel
ABCB1 gene affects the susceptibility to clopidogrel; ABCB1 gene polymorphism affects the susceptibility to clopidogrel; ABCB1 gene SNP affects the susceptibility to clopidogrel
clopidogrel results in decreased activity of ABCB1 protein

PMID:17112805 PMID:19106083 PMID:19934793 PMID:20180610 PMID:21900887

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5AP mRNA]

NCBI chr13:30,713,485...30,764,426
Ensembl chr13:30,713,478...30,764,426

G

Rho GTPase activating protein 31

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ARHGAP31 mRNA]

NCBI chr 3:119,294,383...119,420,714
Ensembl chr 3:119,294,383...119,420,714

G

brain derived neurotrophic factor

decreases secretion

clopidogrel results in decreased secretion of BDNF protein

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

complement C4B (Chido/Rodgers blood group)

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of C4B mRNA]

NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418

G

calcineurin binding protein 1

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CABIN1 mRNA]

NCBI chr22:24,011,304...24,178,628
Ensembl chr22:24,011,192...24,178,628

G

calcium/calmodulin dependent protein kinase kinase 2

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CAMKK2 mRNA]

NCBI chr12:121,237,692...121,297,819
Ensembl chr12:121,237,675...121,298,308

G

C-C motif chemokine ligand 11

increases expression

clopidogrel results in increased expression of CCL11 mRNA

NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334

G

C-C motif chemokine ligand 4

increases expression

clopidogrel results in increased expression of CCL4 mRNA

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 5

increases expression

clopidogrel results in increased expression of CCL5 mRNA

NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793

G

CD40 ligand

multiple interactions
decreases expression

clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]
clopidogrel results in decreased expression of CD40LG protein
Clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD40LG protein]

PMID:11297035 PMID:17043144 PMID:19155974 PMID:30537341

NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390

G

CD86 molecule

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA]

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

chloride voltage-gated channel 7

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CLCN7 mRNA]

NCBI chr16:1,444,935...1,475,028
Ensembl chr16:1,444,934...1,475,077

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2RB mRNA]

NCBI chr22:36,913,628...36,940,439
Ensembl chr22:36,913,628...36,940,439

G

cytochrome P450 family 1 subfamily A member 1

decreases activity

Clopidogrel results in decreased activity of CYP1A1 protein

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

increases oxidation
multiple interactions

CYP1A2 protein results in increased oxidation of clopidogrel
CYP1A2 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; furafylline inhibits the reaction [CYP1A2 protein results in increased oxidation of clopidogrel]

PMID:19170597 PMID:19812348

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 1 subfamily B member 1

decreases activity

Clopidogrel results in decreased activity of CYP1B1 protein

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 2 subfamily B member 6

increases oxidation
multiple interactions
increases expression

CYP2B6 protein results in increased oxidation of clopidogrel
[Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA
Clopidogrel results in increased expression of CYP2B6 mRNA

PMID:19812348 PMID:31312845

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions
increases oxidation
increases metabolic processing
decreases response to substance
increases response to substance
decreases metabolic processing
affects abundance
affects response to substance

ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein]; CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene polymorphism results in decreased metabolism of and results in decreased activity of clopidogrel; CYP2C19 gene SNP promotes the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]; CYP2C19 protein results in increased metabolism of and results in increased activity of clopidogrel; CYP2C19 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]
CYP2C19 protein results in increased metabolism of clopidogrel
CYP2C19 gene polymorphism results in decreased susceptibility to clopidogrel; CYP2C19 gene SNP results in decreased susceptibility to clopidogrel
CYP2C19 gene polymorphism results in increased susceptibility to clopidogrel; CYP2C19 gene SNP results in increased susceptibility to clopidogrel
CYP2C19 gene polymorphism results in decreased metabolism of clopidogrel; CYP2C19 gene SNP results in decreased metabolism of clopidogrel
CYP2C19 gene polymorphism affects the abundance of clopidogrel metabolite
CYP2C19 gene affects the susceptibility to clopidogrel; CYP2C19 gene polymorphism affects the susceptibility to clopidogrel; CYP2C19 gene SNP affects the susceptibility to clopidogrel

PMID:16772608 PMID:17697139 PMID:17900275 PMID:18532997 PMID:18577829 More...

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 8

multiple interactions

CYP2C8 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions
decreases metabolic processing
affects response to substance

CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C9 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite
CYP2C9 gene SNP results in decreased metabolism of clopidogrel
CYP2C9 gene SNP affects the susceptibility to clopidogrel

PMID:17900275 PMID:19170597 PMID:19926050 PMID:19934793

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily D member 6

multiple interactions

CYP2D6 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite

NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865

G

cytochrome P450 family 3 subfamily A member 4

affects response to substance
increases expression
increases response to substance
multiple interactions
increases degradation

CYP3A4 gene polymorphism affects the susceptibility to clopidogrel
Clopidogrel results in increased expression of CYP3A4 mRNA
CYP3A4 protein results in increased susceptibility to clopidogrel
CYP3A4 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of clopidogrel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to clopidogrel]

PMID:16645157 PMID:19170597 PMID:22651985 PMID:31312845

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 5

affects response to substance
multiple interactions

CYP3A5 gene polymorphism affects the susceptibility to clopidogrel
CYP3A5 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite

PMID:16754899 PMID:19170597

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

dual specificity phosphatase 1

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of DUSP1 mRNA]

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

coagulation factor II, thrombin

multiple interactions

clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein]

NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506

G

coagulation factor II thrombin receptor

affects response to substance

F2R gene SNP affects the susceptibility to clopidogrel

NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770

G

coagulation factor III, tissue factor

multiple interactions

Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]

NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Clopidogrel results in decreased expression of G6PC1 mRNA

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

intercellular adhesion molecule 1

decreases expression

clopidogrel results in decreased expression of ICAM1 mRNA; clopidogrel results in decreased expression of ICAM1 protein

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

interleukin 10 receptor subunit alpha

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL10RA mRNA]

NCBI chr11:117,986,394...118,003,037
Ensembl chr11:117,986,370...118,003,037

G

interleukin 13

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL13 mRNA]

NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110

G

interleukin 1 beta

multiple interactions

Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 4

increases expression

clopidogrel results in increased expression of IL4 mRNA

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 6

multiple interactions
decreases expression
increases response to substance

clopidogrel promotes the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]
clopidogrel results in decreased expression of IL6 mRNA
IL6 protein results in increased susceptibility to clopidogrel
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:17537833 PMID:19155974 PMID:24793913 PMID:24849676

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

integrin subunit alpha 2

multiple interactions

ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel]

PMID:15205592 PMID:16214444

NCBI chr 5:52,989,352...53,094,779
Ensembl chr 5:52,989,340...53,094,779

G

integrin subunit beta 3

decreases response to substance
affects response to substance

ITGB3 gene SNP results in decreased susceptibility to clopidogrel
ITGB3 gene SNP affects the susceptibility to clopidogrel

PMID:15166949 PMID:19530321

NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743

G

leukotriene B4 receptor

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of LTB4R1 mRNA]

NCBI chr14:24,311,502...24,318,036
Ensembl chr14:24,311,450...24,318,036

G

mitogen-activated protein kinase 3

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK3 mRNA]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

methylcrotonyl-CoA carboxylase subunit 2

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of MCCC2 mRNA]

NCBI chr 5:71,587,340...71,658,706
Ensembl chr 5:71,579,531...71,658,706

G

mediator complex subunit 1

multiple interactions

Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]

NCBI chr17:39,404,285...39,451,263
Ensembl chr17:39,404,285...39,451,272

G

microRNA 155

increases expression

Clopidogrel results in increased expression of MIR155 mRNA

NCBI chr21:25,573,980...25,574,044
Ensembl chr21:25,573,980...25,574,044

G

microRNA 17

decreases expression

Clopidogrel results in decreased expression of MIR17 mRNA

NCBI chr13:91,350,605...91,350,688
Ensembl chr13:91,350,605...91,350,688

G

microRNA 363

increases expression

Clopidogrel results in increased expression of MIR363 mRNA

NCBI chr X:134,169,378...134,169,452
Ensembl chr X:134,169,378...134,169,452

G

microRNA 663a

increases expression

Clopidogrel results in increased expression of MIR663A mRNA

NCBI chr20:26,208,186...26,208,278
Ensembl chr20:26,208,186...26,208,278

G

matrix metallopeptidase 9

decreases activity

clopidogrel results in decreased activity of MMP9 protein

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

myeloperoxidase

multiple interactions

Clopidogrel inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of MPO protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]

PMID:20133375 PMID:30537341

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

nuclear receptor subfamily 1 group I member 3

multiple interactions
affects localization

[Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; Clopidogrel binds to and results in increased activity of NR1I3 protein alternative form; Clopidogrel inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]
Clopidogrel affects the localization of NR1I3 protein mutant form

NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244

G

occludin

decreases expression
multiple interactions

clopidogrel results in decreased expression of OCLN protein
SB 203580 inhibits the reaction [clopidogrel results in decreased expression of OCLN protein]

NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104

G

purinergic receptor P2Y12

multiple interactions
increases response to substance
affects response to substance

clopidogrel binds to and results in decreased activity of P2RY12 protein; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]
P2RY12 protein results in increased susceptibility to clopidogrel
P2RY12 gene affects the susceptibility to clopidogrel; P2RY12 gene SNP affects the susceptibility to clopidogrel; P2RY12 protein affects the susceptibility to clopidogrel

PMID:11413167 PMID:15933261 PMID:18404433 PMID:18485500 PMID:18577829 More...

NCBI chr 3:151,336,843...151,384,753
Ensembl chr 3:151,336,843...151,384,753

G

phosphoenolpyruvate carboxykinase 1

increases expression

Clopidogrel results in increased expression of PCK1 mRNA

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

platelet derived growth factor subunit B

decreases expression

clopidogrel results in decreased expression of PDGFB mRNA; clopidogrel results in decreased expression of PDGFB protein

NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982

G

paraoxonase 1

affects response to substance
multiple interactions

PON1 gene polymorphism affects the susceptibility to clopidogrel
PON1 protein results in increased metabolism of and results in increased activity of clopidogrel

NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532

G

protein kinase C beta

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of PRKCB mRNA]

NCBI chr16:23,835,983...24,220,611
Ensembl chr16:23,835,983...24,220,611

G

RAN, member RAS oncogene family

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of RAN mRNA]

NCBI chr12:130,872,066...130,877,678
Ensembl chr12:130,872,037...130,877,678

G

S100 calcium binding protein A11

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of S100A11 mRNA]

NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907

G

stearoyl-CoA desaturase

decreases expression

Clopidogrel results in decreased expression of SCD mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

selectin E

decreases expression

clopidogrel results in decreased expression of SELE mRNA; clopidogrel results in decreased expression of SELE protein

NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705

G

selectin P

multiple interactions
decreases expression

Clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SELP protein]
clopidogrel results in decreased expression of SELP mRNA; clopidogrel results in decreased expression of SELP protein

PMID:17043144 PMID:19155974 PMID:30537341

NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193

G

solute carrier family 3 member 1

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SLC3A1 mRNA]

NCBI chr 2:44,275,480...44,322,437
Ensembl chr 2:44,275,458...44,321,494

G

signal transducer and activator of transcription 2

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of STAT2 mRNA]

NCBI chr12:56,341,597...56,360,107
Ensembl chr12:56,341,597...56,360,203

G

succinate-CoA ligase ADP-forming subunit beta

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SUCLA2 mRNA]

NCBI chr13:47,942,656...48,001,273
Ensembl chr13:47,745,736...48,037,968

G

transforming growth factor beta 1

multiple interactions
increases expression

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TGFB1 mRNA]
clopidogrel results in increased expression of TGFB1 mRNA

PMID:19155974 PMID:19172522

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

thrombospondin 1

increases expression

clopidogrel results in increased expression of THBS1; clopidogrel results in increased expression of THBS1 mRNA; clopidogrel results in increased expression of THBS1 protein

PMID:9447704 PMID:11875746

NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466

G

thyroid hormone responsive

increases expression

Clopidogrel results in increased expression of THRSP mRNA

NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351

G

tight junction protein 1

decreases expression
multiple interactions

clopidogrel results in decreased expression of TJP1 protein
SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein]

NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915

G

transmembrane protein 69

multiple interactions

clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TMEM69 mRNA]

NCBI chr 1:45,688,181...45,694,436
Ensembl chr 1:45,688,181...45,694,436

G

tumor necrosis factor

increases expression
multiple interactions

clopidogrel results in increased expression of TNF mRNA
Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

PMID:19155974 PMID:30537341

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

increases expression

clopidogrel results in increased expression of TP53 mRNA; clopidogrel results in increased expression of TP53 protein

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

vasodilator stimulated phosphoprotein

multiple interactions

CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein]

NCBI chr19:45,507,479...45,526,983
Ensembl chr19:45,506,579...45,526,989

ticlopidine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
decreases expression

Ticlopidine results in decreased activity of ABCB11 protein
Ticlopidine results in decreased expression of ABCB11 mRNA

PMID:22646477 PMID:27765674

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily C member 2

decreases activity
increases expression

Ticlopidine results in decreased activity of ABCC2 protein
Ticlopidine results in increased expression of ABCC2 mRNA

PMID:22646477 PMID:27765674

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

increases expression

Ticlopidine results in increased expression of ABCC3 mRNA

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

ATP binding cassette subfamily C member 4 (PEL blood group)

increases expression

Ticlopidine results in increased expression of ABCC4 mRNA

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

caspase 3

increases activity
multiple interactions

Ticlopidine results in increased activity of CASP3 protein
Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

increases activity
multiple interactions

Ticlopidine results in increased activity of CASP7 protein
Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP7 protein]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

collagen type XVIII alpha 1 chain

increases expression

Ticlopidine results in increased expression of COL18A1 protein

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions
decreases activity

CYP1A2 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide]
Ticlopidine results in decreased activity of CYP1A2 protein

PMID:10759690 PMID:19053182 PMID:19170597

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 1 subfamily B member 1

decreases activity

Ticlopidine results in decreased activity of CYP1B1 protein

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

cytochrome P450 family 2 subfamily B member 6

multiple interactions
decreases activity

Ticlopidine binds to and results in decreased activity of CYP2B6 protein; Ticlopidine inhibits the reaction [CYP2B6 protein affects the metabolism of Endosulfan]; Ticlopidine inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion]
Ticlopidine results in decreased activity of CYP2B6 protein

PMID:16855053 PMID:19328226 PMID:23850985 PMID:28887089 PMID:33253783

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions
decreases activity

CYP2C19 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide]
Ticlopidine results in decreased activity of CYP2C19 protein

PMID:10759690 PMID:15333513 PMID:15860655 PMID:16049126 PMID:19053182 More...

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 8

multiple interactions

CYP2C8 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions
decreases activity

CYP2C9 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 4'-hydroxytolbutamide]; Ticlopidine inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]
Ticlopidine results in decreased activity of CYP2C9 protein

PMID:19170597 PMID:21915887

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily D member 6

decreases activity
multiple interactions

Ticlopidine results in decreased activity of CYP2D6 protein
CYP2D6 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite

PMID:10759690 PMID:19170597

NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865

G

cytochrome P450 family 3 subfamily A member 4

multiple interactions
increases response to substance
increases degradation

CYP3A4 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of Ticlopidine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Ticlopidine]; Ticlopidine promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]

PMID:19170597 PMID:19299527 PMID:22651985

NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248

G

cytochrome P450 family 3 subfamily A member 5

multiple interactions

CYP3A5 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

major histocompatibility complex, class I, A

affects response to substance

HLA-A gene polymorphism affects the susceptibility to Ticlopidine

NCBI chr 6:29,942,532...29,945,870
Ensembl chr 6:29,941,260...29,949,572

G

heme oxygenase 1

multiple interactions
increases expression

1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

progesterone receptor

multiple interactions

Ticlopidine binds to and results in decreased activity of PGR protein

NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813

G

solute carrier family 10 member 1

decreases expression

Ticlopidine results in decreased expression of SLC10A1 mRNA

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 47 member 1

multiple interactions

Ticlopidine affects the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034

G

solute carrier family 47 member 2

multiple interactions

Ticlopidine affects the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979

G

thrombospondin 1

affects expression

Ticlopidine affects the expression of THBS1 mRNA

NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466

G

transmembrane serine protease 2

increases expression

Ticlopidine results in increased expression of TMPRSS2 mRNA

NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116

G

UDP glucuronosyltransferase family 1 member A1

increases expression

Ticlopidine results in increased expression of UGT1A1 mRNA

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

vascular endothelial growth factor A

decreases activity

Ticlopidine results in decreased activity of VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

tranexamic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

Tranexamic Acid inhibits the reaction [Rotenone results in increased expression of BAX protein]

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

Tranexamic Acid inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

multiple interactions

Tranexamic Acid inhibits the reaction [Rotenone results in increased cleavage of and results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

Tranexamic Acid inhibits the reaction [Rotenone results in increased cleavage of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

collagen type I alpha 1 chain

multiple interactions

Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of COL1A1 mRNA]

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

keratin 19

multiple interactions

Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of KRT19 protein]

NCBI chr17:41,523,617...41,528,308
Ensembl chr17:41,523,617...41,528,308

G

poly(ADP-ribose) polymerase 1

multiple interactions

Tranexamic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]

NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154

G

transforming growth factor beta 2

multiple interactions

Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]

NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619

G

TIMP metallopeptidase inhibitor 1

multiple interactions

Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TIMP1 mRNA]

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26034
role	25961
application	25172
pharmaceutical	24558
drug	24544
fibrin modulating drug	167
antifibrinolytic drug +	49
cilostazol	52
ticlopidine +	86
tirofiban +	0

paths to the root